Lead Sponsor

University of Colorado, Denver

Age

30 - 70 years

Sex

ALL

Healthy Volunteers

No

•CKD stage 3
•urine albumin to creatinine ratio 200-5000 mg/g
•blood pressure \<140/90 mmHg
•use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker with stable dose for 4 weeks
•history of diabetes type 1 or 2
•BMI \<40 kg/m2
•Stable antihypertensive regimen for at least one month prior to enrollment
•Stable diabetes regimen for at least one month prior to enrollment
•Sedentary or recreationally active (\<2 days of vigorous aerobic exercise as vigorous exercise may affect vascular function measurements)
•Able to provide consent

•Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year
•Uncontrolled hypertension
•Factors judged to limit adherence to interventions (e.g. history of medication noncompliance, noncompliance with follow up visits, significant cognitive impairment, etc.)
•Anticipated initiation of dialysis or kidney transplantation within 3 months
•Current participation in another research study
•Pregnancy or planning to become pregnant or currently breastfeeding
•Allergy to aspirin
•Severe hepatic impairment (Child-Pugh Class C)
•History of major psychiatric disorder
•Use of inhaled or systemic corticosteroids or long-acting beta agonists (higher risk of neuropsychiatric reaction)
•Current use of SGLT2 inhibitor
•Current use of phenobarbital, rifampin or carbamazepine.